DrugPatentWatch Database Preview

TOBI PODHALER Drug Profile

« Back to Dashboard

When do Tobi Podhaler patents expire, and when can generic versions of Tobi Podhaler launch?

Tobi Podhaler is a drug marketed by Novartis and is included in one NDA. There are seven patents protecting this drug.

The generic ingredient in TOBI PODHALER is tobramycin. There are eighteen drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the tobramycin profile page.

Summary for TOBI PODHALER

US Patents:	7
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	53
Clinical Trials:	6
Patent Applications:	4,534
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for TOBI PODHALER
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TOBI PODHALER
DailyMed Link:	TOBI PODHALER at DailyMed

Pharmacology for TOBI PODHALER

Ingredient-type	Aminoglycosides
Drug Class	Aminoglycoside Antibacterial

Medical Subject Heading (MeSH) Categories for TOBI PODHALER

Anti-Bacterial Agents

Synonyms for TOBI PODHALER

(1S,2S,3R,4S,6R)-4,6-diamino-3-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyloxy)-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside

(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside

(2S,3R,4S,5S,6R)-4-amino-2-(((1S,2S,3R,4S,6R)-4,6-diamino-3-(((2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxytetrahydro-2H-pyran-2-yl)oxy)-2-hydroxycyclohexyl)oxy)-6-(hydroxymethyl)tetrahyd

(2S,3R,4S,5S,6R)-4-amino-2-(((1S,2S,3R,4S,6R)-4,6-diamino-3-(((2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxytetrahydro-2H-pyran-2-yl)oxy)-2-hydroxycyclohexyl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diol

(2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxy-tetrahydropyran-2-yl]oxy-2-hydroxy-cyclohexoxy]-6-(hydroxymethyl)tetrahydropyran-3,5-diol

(2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol

(2S,3R,4S,5S,6R)-4-amino-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxymethyl)oxane-3,5-diol

1-Epitobramycin

11098-01-4

11111-45-8

3'-Deoxykanamycin B

32986-56-4

34337-51-4

37321-13-4

4-(2,6-Diamino-2,3,6-trideoxy-alpha-D-glycopyranosyl)-6-(3-amino-3-deoxy-alpha-D-glycopyranosyl)-2-deoxystreptamine

4-AMINO-2-[4,6-DIAMINO-3-(3-AMINO-6-AMINOMETHYL-5-HYDROXY-TETRAHYDRO-PYRAN-2-YLOXY)-2-HYDROXY-CYCLOHEXYLOXY]-6-HYDROXYMETHYL-TETRAHYDRO-PYRAN-3,5-DIOL

49842-07-1 (Sulfate)

54330-95-9

70322-33-7

986T564

A-8891

AB00052438_13

AB00052438_14

AB00052438-12

AB00513858

AB2000616

AC1L1VI0

AC1Q2AOW

AK481288

AKOS016339662

Aktob

AN-9578

AOB5629

API0004434

BDBM50366778

Bethkis (TN)

BIDD:GT0503

BIT0802

BPBio1_000647

BRN 1357507

Brulamycin

BSPBio_000587

BSPBio_002036

C-22669

C00397

C18H37N5O9

CA006492

CA009438

CAS-32986-56-4

CC-35084

CCG-39936

CHEBI:28864

CHEMBL1747

CPD000058793

CS-2547

D-Streptamine, O-3-amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[2,6-diamino-2,3,6-trideoxy-.alpha.-D-ribo-hexopyranosyl-(1->4)]-2-deoxy-

D-Streptamine, O-3-amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[2,6-diamino-2,3,6-trideoxy-.alpha.-D-ribohexopyranosyl-(1->4)]-2-deoxy-

D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl-(1->4))-2-deoxy-

D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl-(1-4))-2-deoxy-

D00063

DB00684

Deoxykanamycin B

Distobram

DR002903

DSSTox_CID_3680

DSSTox_GSID_23680

DSSTox_RID_77144

DTXSID8023680

EINECS 251-322-5

Gernebcin

Gotabiotic

HMS2090B16

HMS2092M17

HMS2096N09

HSDB 3259

HY-B0441

J10405

KBio2_001552

KBio2_004120

KBio2_006688

KBio3_001536

KBioGR_001104

KBioSS_001552

KS-1405

Lilly 47663

LS-146940

LS-187329

MFCD00077885

MLS000069544

MolPort-003-665-548

NCGC00016814-01

NCGC00178852-01

NCGC00178852-02

Nebcin

Nebcin (Sulfate)

Nebicin

NEBRAMYCIN

Nebramycin 6

Nebramycin factir 6

Nebramycin factor 6

Nebramycin VI

Nebramycin-Faktor 6

NF 6

NLVFBUXFDBBNBW-PBSUHMDJSA-N

NSC 180514

NSC-757352

NSC757352

O-?3-?AMINO-?3-?DEOXY-?ALPHA-?D-?GLUCOPYRANOSYL-?(1?6)-?O-?[2,?6-?DIAMINO-?2,?3,?6-?TRIDEOXY-?ALPHA-?D-?RIBO-?HEXOPYRANOSYL-?(1?4)]-?2-?DEOXY-?D-?STREPTAMINE

O-[3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-->6)]-O-[2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-->4)]-2-deoxy-D-streptamine

O-[3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)]-O-[2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl-(1->4)]-2-deoxy-D-streptamine

O-3-Amino-3-deoxy-?-D-glucopyranosyl-(1-6)-O-[2,6-diamino-2,3,6-trideoxy-?-D-ribohexopyranosyl-(1-4)]-2-deoxy-D-streptamine

O-3-Amino-3-deoxy-a-D-glucopyranosyl-(1-6)-O-[2,6-diamino-2,3,6-trideoxy-a -D-ribo-hexopyranosyl-(1-4)]-2-deoxy-D-streptamine

O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl-(1-6))-2-deoxy-L-streptamine

O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-4))-2-deoxy-D-streptamine

O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-4))-2-deoxy-D-streptamine

Obramycin

Pharmakon1600-01500579

Prestwick3_000544

Q-201837

ro-2H-pyran-3,5-diol

s2514

SAM001246911

SBI-0051915.P003

SC-45657

SCHEMBL2838

SMR000058793

SPBio_000295

Spectrum_001072

SPECTRUM1500579

Spectrum2_000078

Spectrum3_000588

Spectrum4_000752

Spectrum5_001038

SPRC-AB01

SR-05000001726

SR-05000001726-2

Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-6))-2-deoxy-, D-

Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-tyrideoxy-alpha-D-ribohexopyranosyl-(1-6))-2-deoxy-, D-

Sybryx

Tenebrimycin

Tenemycin

TOA-(1-6)2TB-(4-1)TOC

TOA-(1-6)TOB-(4-1)TOC

Tobacin

Tobi

Tobi (TN)

Tobracin

Tobracin (TN)

Tobradex

Tobradistin

Tobralex

Tobramaxin

Tobramicin

Tobramicina

Tobramicina [INN-Spanish]

Tobramitsetin

Tobramycetin

tobramycin

Tobramycin (JP17/USP)

Tobramycin [USAN:BAN:INN:JAN]

Tobramycin Base

Tobramycin for Inhalation

tobramycin solution for inhalation

TOBRAMYCIN SULFATE

Tobramycin, Antibiotic for Culture Media Use Only

Tobramycine

Tobramycine [INN-French]

Tobramycinum

Tobramycinum [INN-Latin]

Tobrased

Tobrasone

Tobrex

Tobrex (TN)

torbamycin

Tox21_110626

TOY

UNII-VZ8RRZ51VK

vantobra

VZ8RRZ51VK

ZINC8214692

ZX-AFC000193

US Patents and Regulatory Information for TOBI PODHALER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	TOBI PODHALER	tobramycin	POWDER;INHALATION	201688-001	Mar 22, 2013		RX	Yes	Yes			Y
Novartis	TOBI PODHALER	tobramycin	POWDER;INHALATION	201688-001	Mar 22, 2013		RX	Yes	Yes			Y
Novartis	TOBI PODHALER	tobramycin	POWDER;INHALATION	201688-001	Mar 22, 2013		RX	Yes	Yes			Y

Expired US Patents for TOBI PODHALER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	TOBI PODHALER	tobramycin	POWDER;INHALATION	201688-001	Mar 22, 2013

International Patents for TOBI PODHALER

Country	Document Number	Estimated Expiration
Spain	2525087
Mexico	PA04005865
European Patent Office	1280520

Supplementary Protection Certificates for TOBI PODHALER

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2015000021	Germany		PRODUCT NAME: TOBRAMYCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/10/652/001-003 20110720
1273292/01	Switzerland		PRODUCT NAME: TOBRAMYCIN; REGISTRATION NO/DATE: SWISSMEDIC 58751 28.05.2009
678	Luxembourg		PRODUCT NAME: TOBRAMYCINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE. FIRST REGISTRATION: 20110725